BridgeBio’s lean focus on genetic drivers scores 2nd drug approval in 3 months

The newest oral drug will cost about $21,500 per month to tackle one of the most aggressive forms of cancer. But the company also expects mid-stage clinical results later this year for the same drug as a treatment for a form of dwarfism.